Integra LifeSciences vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Integra LifeSciences Holdings (IART)

Q3 202615 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

August 202615 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

Latest15 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.